The potential of 12/15-lipoxygenase inhibitors in stroke therapy

Future Medicinal Chemistry

Volumn 6, Issue 17, 2014, Pages 1853-1855

  Van Leyen, Klaus ^a   Holman, Theodore R ^b   Maloney, David J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

edema; eicosanoid; hemorrhage; ischemia; lipoxygenase; oxidative stress; stroke; tissue plasminogen activator

Indexed keywords

ALPHA TOCOTRIENOL; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 12 LIPOXYGENASE INHIBITOR; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE INHIBITOR; BAICALEIN; CURCUMIN; DISUFENTON SODIUM; NORDIHYDROGUAIARETIC ACID; OXYGENASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; 12-15-LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NEUROPROTECTIVE AGENT;

BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DRUG POTENCY; HUMAN; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; ANIMAL; APOPTOSIS; CELL LINE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOUSE; STROKE;

ANIMALS; APOPTOSIS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; CELL LINE; HUMANS; LIPOXYGENASE INHIBITORS; MICE; NEUROPROTECTIVE AGENTS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84919830503     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.129     Document Type: Review

References (20)

1. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 129(3), e28-e292 (2014
2. Jin G, Arai K, Murata Y et al. Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke 39(9), 2538-2543 (2008
3. Yigitkanli K, Pekcec A, Karatas H et al. Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann. Neurol. 73(1), 129-135 (2013
4. Heemskerk J, Farkas R, Kaufmann P. Neuroscience networking: linking discovery to drugs. Neuropsychopharmacology 37(1), 287-289 (2012
5. Kenyon V, Chorny I, Carvajal WJ, Holman TR, Jacobson MP. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J. Med. Chem. 49(4), 1356-1363 (2006
6. Carroll J, Jonsson EN, Ebel R, Hartman MS, Holman TR, Crews P. Probing sponge-derived terpenoids for human 15-lipoxygenase inhibitors. J. Org. Chem. 66(21), 6847-6851 (2001
7. Whitman S, Gezginci M, Timmermann BN, Holman TR. Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. J. Med. Chem. 45(12), 2659-2661 (2002
8. Amagata T, Whitman S, Johnson TA et al. Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J. Nat. Prod. 66(2), 230-235 (2003
9. Cichewicz RH, Kenyon VA, Whitman S et al. Redox inactivation of human 15-lipoxygenase by marine-derived meroditerpenes and synthetic chromanes: archetypes for a unique class of selective and recyclable inhibitors. J. Am. Chem. Soc. 126(45), 14910-14920 (2004
10. Vasquez-Martinez Y, Ohri RV, Kenyon V, Holman TR, Sepulveda-Boza S. Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorg. Med. Chem. 15(23), 7408-7425 (2007
11. Deschamps JD, Kenyon VA, Holman TR. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg. Med. Chem. 14(12), 4295-4301 (2006
12. Rai G, Kenyon V, Jadhav A et al. Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1. J. Med. Chem. 53(20), 7392-7404 (2010
13. Ngu K, Weinstein DS, Liu W et al. Pyrazole-based sulfonamide and sulfamides as potent inhibitors of mammalian 15-lipoxygenase. Bioorg. Med. Chem. Lett. 21(14), 4141-4145 (2011
14. Weinstein DS, Liu W, Ngu K et al. Discovery of selective imidazole-based inhibitors of mammalian 15-lipoxygenase: highly potent against human enzyme within a cellular environment. Bioorg. Med. Chem. Lett. 17(18), 5115-5120 (2007
15. Weinstein DS, Liu W, Gu Z et al. Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase. Bioorg. Med. Chem. Lett. 15(5), 1435-1440 (2005
16. Khanna S, Roy S, Ryu H et al. Molecular basis of vitamin E action: Tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J. Biol. Chem. 278(44), 43508-43515 (2003
17. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14(11), 2219-2225 (1993
18. Sendobry SM, Cornicelli JA, Welch K et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol. 120(7), 1199-1206 (1997
19. van Leyen K, Arai K, Jin G et al. Novel lipoxygenase inhibitors as neuroprotective reagents. J. Neurosci. Res. 86(4), 904-909 (2008
20. Rai G, Joshi N, Jung JE et al. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J. Med. Chem. 57(10), 4035-4048 (2014)